ORIGINAL RESEARCH

Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center

Claire J. Peet, BM BCh, MRCP; Dorota Rowczenio, PhD; Ebun Omoyinmi, PhD; Charalampia Papadopoulou, MD, PhD; Bella Ruth R. Mapalo, BSc; Michael R. Wood, MSc; Francesca Capon, PhD; Helen J. Lachmann, MD, FRCP, FRCPath

BACKGROUND: Idiopathic recurrent pericarditis (IRP) is an orphan disease that carries significant morbidity, partly driven by corticosteroid dependence. Innate immune modulators, colchicine and anti-interleukin-1 agents, pioneered in monogenic autoinflammatory diseases, have demonstrated remarkable efficacy in trials, suggesting that autoinflammation may contribute to IRP. This study characterizes the phenotype of patients with IRP and monogenic autoinflammatory diseases, and establishes whether autoinflammatory disease genes are associated with IRP.

METHODS AND RESULTS: We retrospectively analyzed the medical records of patients with IRP (n=136) and monogenic autoinflammatory diseases (n=1910) attending a national center (London, UK) between 2000 and 2021. We examined 4 genes (MEFV, MVK, NLRP3, TNFRSF1A) by next-generation sequencing in 128 patients with IRP and compared the frequency of rare deleterious variants to controls obtained from the Genome Aggregation Database. In this cohort of patients with IRP, corticosteroid dependence was common (39/136, 28.7%) and was associated with chronic pain (adjusted odds ratio 2.8 [95% CI, 1.3–6.5], P=0.012). IRP frequently manifested with systemic inflammation (raised C-reactive protein [121/136, 89.0%] and extrapericardial effusions [68/136, 50.0%]). Pericarditis was observed in all examined monogenic autoinflammatory diseases (0.4%–3.7% of cases). Rare deleterious MEFV variants were more frequent in IRP than in ancestry-matched controls (allele frequency 9/200 versus 2932/129 200, P=0.040).

CONCLUSIONS: Pericarditis is a feature of interleukin-1 driven monogenic autoinflammatory diseases and IRP is associated with variants in MEFV, a gene involved in interleukin-1β processing. We also found that corticosteroid dependence in IRP is associated with chronic noninflammatory pain. Together these data implicate autoinflammation in IRP and support reducing reliance on corticosteroids in its management.

Key Words: autoinflammation ■ inflammation ■ pericarditis

See Editorial by Roubille et al.
increased recurrence risk, their use in IRP remains widespread.\textsuperscript{1–4} Consequently, there is a need to understand the mechanisms driving IRP, to guide management that minimizes treatment-associated harm.

A leading hypothesis is that IRP is mediated by autoinflammation.\textsuperscript{1} Autoinflammation is defined as excessive activity of the innate immune system, in the absence of an extrinsic stressor or autoreactive antibodies or T cells.\textsuperscript{5} It is best understood in the context of the monogenic systemic autoinflammatory disease (SAID). The prototypic SAID is familial Mediterranean fever (FMF), an autosomal recessive disease caused by mutations in the \textit{MEFV} gene that result in overactivity of the pyrin inflammasome and interleukin (IL)-1β secretion, which presents with episodic serositis.\textsuperscript{5}

FMF prognosis has been transformed by prophylactic use of colchicine, an ancient drug that acts on the cytoskeleton, with pleiotropic effects including inhibition of inflammasome formation.\textsuperscript{6,7} More recently, biologic anti-IL-1 agents, including anakinra and rilonacept, have revolutionized the management of colchicine-refractory FMF and 3 other monogenic SAIDs: cryopyrin-associated periodic syndrome (CAPS), TNF receptor–associated periodic syndrome (TRAPS), and mevalonate kinase deficiency (MKD).\textsuperscript{6,8} These developments have highlighted the central role of IL-1 in autoinflammation and provided a paradigm for the targeted treatment of relapsing inflammatory diseases. Importantly, randomized controlled trials have shown that these same agents are effective in IRP (Table 1).\textsuperscript{9–13} This was reflected both in the inclusion of colchicine and anakinra in the 2015 European Society of Cardiology (ESC) guidelines and the recent US Food and Drug Administration licensing of rilonacept and, interestingly, suggests that IRP may be mediated by autoinflammatory pathways.\textsuperscript{14}

Despite the similarities between SAID and IRP, it is yet to be established whether clinical features or genetic determinants of autoinflammation are seen in IRP, and studies evaluating pericardial involvement in IL-1-mediated SAID are lacking. Here, we begin by characterizing the phenotype of 136 patients with IRP and analyze clinical features that are associated with complicated disease. We then conduct the first systematic assessment of pericarditis across IL-1-mediated SAIDs. We conclude with analysis of the 4 genes that cause these conditions in 128 patients with IRP, to identify whether the presence of variants in 1 or more of these genes is associated with an increased risk of IRP. Together these approaches evaluate the extent to which clinical features and genetic determinants of autoinflammation characterize IRP.

**METHODS**

The data underlying this article will be shared upon reasonable request to the corresponding author.
**Table 1. Summary of Randomized Controlled Trials of Interventions in Recurrent Pericarditis**

| Design                  | Colchicine                                                                 |
|-------------------------|----------------------------------------------------------------------------|
|                          | Anti-IL-1 trap*                                                            |
|                          | IL-1 receptor antagonist                                                   |
|                          | Anakinra, AIRTRIP12                                                        |
|                          | Rilonacept, RHAPSODY13                                                     |
|                          | CORP-211                                                                  |
|                          | CORP-9                                                                    |
|                          | CORP-10                                                                   |
|                          | CORP-21                                                                  |
|                          | RCT, double-blind, multicenter                                            |
|                          | RCT, double-blind, multicenter                                            |
|                          | RCT, double-blind, multicenter                                            |
|                          | Double-blind, multicenter                                                |
| Inclusion criteria       | 1st recurrence                                                             |
|                          | ≥2nd recurrence, ≥4th recurrence, CRP ≥10 mg/L                            |
|                          | ≥2nd recurrence, CRP ≥10 mg/L                                             |
|                          | ≤2nd recurrence, CRP ≥10 mg/L                                             |
|                          | Pericarditis cause                                                        |
|                          | ID: recurrent pericarditis (83%), autoimmune or postpericardotomy (17%) |
|                          | ID: recurrent pericarditis (82%), autoimmune or postpericardotomy (18%) |
|                          | ID: recurrent pericarditis (83%), post cardiac injury (9%), autoimmune (7%) |
|                          | ID: recurrent pericarditis (100%)                                         |
|                          | ID: recurrent pericarditis (85%), Dressler’s or postpericardotomy (15%)  |
| Randomization criteria   | N/A                                                                       |
|                          | N/A                                                                       |
|                          | N/A                                                                       |
|                          | Complete response and stopped NSAIDs, colchicine, or corticosteroids at 60 d |
|                          | Complete response and stopped NSAIDs, colchicine, or corticosteroids at 60 d |
|                          | Complete response and stopped NSAIDs, colchicine, or corticosteroids at 60 d |
|                          | Randomized withdrawal trial *                                             |
|                          | Randomized withdrawal trial *                                             |
|                          | Randomized withdrawal trial *                                             |
|                          | Double-blind, multicenter                                                |
|                          | Double-blind, multicenter                                                |
|                          | Double-blind, multicenter                                                |
|                          | Double-blind, multicenter                                                |
|                          | Open label, multicenter                                                  |
| Patient number           | 84 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
|                          | 60 randomized                                                             |
| Intervention group regimen | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
|                          | Colchicine 6 mg, 1–2 mg/24 h loading on D0                              |
| Control group regimen    | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
|                          | Placebo                                                                   |
| Primary end point(s)     | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
|                          | Recurrence rate at 60 mo                                                  |
| Definition of recurrence | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |
|                          | Pain and raised CRP, ‖ and 1 of: fever, rub, ECG changes or effusion ^   |

CRP indicates C-reactive protein; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; IL-1, interleukin-1; IRP, idiopathic recurrent pericarditis; N/A, not applicable; NE, not estimated; NSAID, nonsteroidal anti-inflammatory; RCT, randomized control trial; URTI, upper respiratory tract infection; and WCC, white cell count.

* Two further randomized controlled trials of the novel anti-IL-1 trap RPH-104 are currently registered on clinicaltrials.org (NCT04692766, NCT05107934).

† In randomized controlled trials, patients undergo an open label run-in period on anakinra/rilonacept, following which responders are randomized to either the intervention or placebo group. Patients randomized to placebo who experience a disease recurrence are then offered bailout anakinra/rilonacept.

‡ Note pediatric dose adjustments for anakinra (2 mg/kg per 24 h) and rilonacept (4.4 mg/kg loading, 2.2 mg/kg maintenance).

§ New or worsening pericardial effusion.

‖ For AIRTRIP, details of pain and CRP threshold values are not published; for RHAPSODY, pain is defined as pain ≥2 using a numerical scale 0 to 10 and CRP ≥10 mg/L.
This study complies with the Declaration of Helsinki. Informed written consent was provided by all study participants and ethical approval was obtained from the Royal Free Hospital and University College Medical School Research Ethics Committee (REC reference number 06/Q0501/42).

**Patient Ascertainment**
This study included all consecutive patients with a diagnosis of IRP (n=136) or IL-1-mediated monogenic SAIIDs (n=1910) that were reviewed between October 17, 2000 and March 25, 2021 in a single UK reference center (CAPS and autoinflammatory disease treatment service, National Amyloidosis Centre, Royal Free Hospital & UCL Division of Medicine, London). Data pertaining to demographics, comorbidity, clinical presentation, complications, and treatment were gathered from electronic medical records. Participant ethnicity was self-reported and participant ancestry was categorized based on self-reported descent according to groups defined in the Genome Aggregation Database (gnomAD, v2.1.1), thereby facilitating comparison of minor allele frequency with ancestry-matched populations. For patients with monogenic SAIIDs, case notes were reviewed for a history of acute or recurrent pericarditis that met ESC diagnostic criteria. Collection of data from medical records and its analysis was performed from April 1 to August 3, 2021.

**DNA Extraction and Sequencing**
Genomic DNA (n=128) was extracted from whole blood, as previously described, or saliva, collected in OraGENE kits, according to the manufacturer’s protocol, and was stored for future sequencing. Next-generation sequencing was performed using one of two custom Illumina panels (TruSeq panel, n=44; AmpliSeq panel, n=84) that include the four genes: MEFV, MVK, NLRP3, and TNFRSF1A. Full details of the genomic regions covered by each panel are available in Data S1. Next-generation sequencing libraries were prepared using the TruSeq or AmpliSeq Custom Amplicon Method (Illumina). All sequencing was performed on the Illumina MiSeq platform between February 8, 2018 and May 24, 2021.

**Variant Calling and Annotation**
Reads were aligned to the human reference genome (hg19) and variants were called using Somatic Variant Caller (Illumina). Variants identified for each patient were filtered and prioritized using Variant Interpreter Software (Illumina). The analysis of germline alleles (defined as an alternative allele found in ≥35% reads) and somatic variants (defined as an alternative allele seen in 5%–34% reads) was restricted to regions covered at >50× and >200× depth, respectively.

To identify candidate variants, we first selected non-synonymous and splice site variants. These were then cross-referenced against the databases ClinVar [https://www.ncbi.nlm.nih.gov/clinvar/; accessed [19/07/21]] and InFevers [https://infevers.umai-montpellier.fr/; accessed [19/07/21]] to identify known pathogenic or likely pathogenic alleles.16–20 In parallel, variants were annotated according to the minor allele frequency reported on the gnomAD for the corresponding ancestry group. Rare variants (minor allele frequency <0.01) were then subjected to in silico pathogenicity prediction using the Combined Annotation Depletion Dependent tool.21,22 A scaled Combined Annotation Depletion Dependent score >10 was considered evidence of deleterious potential.

**Rare Variant Analysis by Burden Association Testing**
Burden association tests were performed when multiple rare deleterious variants (minor allele frequency <0.01, Combined Annotation Depletion Dependent score >10) were identified in a single gene, by comparing the combined frequency of all rare deleterious variants in cases to that of ancestry-matched controls. Individuals with exome sequencing data available in gnomAD v2.1.1 were used as reference controls. To confirm that cases and controls were appropriately matched, we also undertook a burden association test comparing the combined frequency of synonymous rare variants between the 2 groups. Genetic analysis was performed between June 4 and August 3, 2021.

**Statistical Analysis**
Numerical variables are presented as median ± interquartile range, while categorical data are described as absolute counts and percentages. Differences between groups were assessed with the Mann–Whitney U test for continuous data and the χ² or Fisher exact test for discrete data. Where multiple independent variables were found to be associated with the response variable, these were included in a multiple logistic regression model as explanatory variables, together with sex and age of onset, to account for any confounding effects. All statistical analyses and visualization of data were conducted in R statistics (v4.0.3, https://www.R-project.org). For multiple logistic regression analyses, the adjusted odds ratio (aOR), 95% CI, and P value are reported. P values <0.05 are considered statistically significant.

J Am Heart Assoc. 2022;11:e024931. DOI: 10.1161/JAHA.121.024931
RESULTS

Demographic and Clinical Features of Patients With IRP

We characterized the clinical features of our cohort of 136 patients diagnosed with IRP (Table 2). IRP showed an even sex distribution with a median age of onset of 31 years, and the majority of patients had no comorbidities (83/136, 61.0%). The disease was sporadic in most cases, with family history in a first-degree relative reported in only 6 patients (4.4%). Most affected individuals showed evidence of extrapericardial inflammation during disease flares and, notably, 68/136 (50%) had a history of extrapericardial effusion (pleural effusion and/or ascites). Median follow-up from first to last study visit was 12 months (interquartile range, 5–37 months) and the median time from first pericarditis diagnosis to first visit date was 4 years (interquartile range, 1–7 years) (Figure S1).

Management of Patients With IRP

Treatment details are summarized in Table 2. Colchicine was the most commonly prescribed drug, used in 125/136 patients (91.9%), followed by corticosteroids, in 77/136 (56.6%). Of note, colchicine use at first pericarditis diagnosis was low (31/136, 22.8%), though it was significantly higher in patients diagnosed from 2016, after publication of the 2015 ESC guidelines, compared with those presenting up to and including 2015 (21/46 versus 10/90, \( P < 0.0001 \)) (Figure 1). Corticosteroids were used in the presenting episode in 26/136 cases (19.1%) and more frequently from 2016 onwards (15/46 versus 11/90, \( P = 0.006 \)).

Of the 19/136 individuals (14.0%) who were treated with the recombinant IL-1 receptor antagonist anakinra, 18 received 100 mg daily as prophylaxis. Among those treated with prophylactic anakinra, only 1 episode of acute pericarditis was recorded over a median follow-up period of 24 months. In the affected patient, no further episodes were seen after dose escalation to 200 mg daily.

Factors Associated With Complications in IRP

Acute cardiac complications occurred in a significant minority of patients. Cardiac tamponade, necessitating emergency pericardiocentesis, was reported in 27/136 cases (19.9%) and myocardial involvement, defined as a raised troponin and/or evidence of myocardial inflammation on cardiac MRI, in 15/136 cases (11.0%). Cardiac tamponade was reported during a single episode of acute pericarditis in 26 patients, and in 2 discrete episodes in the remaining individual. Cardiac tamponade was associated with earlier disease onset, although the effect size was small (aOR, 0.96 [95% CI, 0.92–0.99], Table 2. Demographics and Clinical Features of Patients With IRP

| Demographics | All patients with IRP (n=136) |
|--------------|-------------------------------|
| Sex (female), n (%) | 68 (50.0) |
| Onset, median [IQR] | 31.00 [23.0–40.0] |
| Patient reported ethnicity, n (%)* | 68 (50.0) |
| Asian or Asian British | 5 (3.7) |
| Black or Black British | 12 (8.8) |
| Mixed ethnicity | 3 (2.2) |
| Other ethnicity (Arab) | 6 (4.4) |
| Unknown or not disclosed | 1 (0.7) |
| White or White British | 109 (80.1) |
| Family history, n (%)† | 6 (4.4) |
| Year of first confirmed episode of acute pericarditis, n (%) | 90 (66.2) |
| 1991–2015 | 48 (33.8) |
| Comorbidities, n (%) | 53 (39.0) |
| No comorbidity | 83 (61.0) |
| One or more comorbidity‡ | 11 (8.1) |
| Hypertension | 53 (39.0) |
| Osteoporosis or osteopenia | 9 (6.6) |
| Supraventricular arrhythmia | 8 (5.9) |
| Thyroid disease | 7 (5.1) |
| Type 2 diabetes | 5 (3.7) |
| Depression | 5 (3.7) |
| Asthma | 4 (2.9) |
| Previous malignancy | 4 (2.9) |
| Renal disease | 4 (2.9) |
| Endometriosis | 3 (2.2) |
| Clinical features of acute pericarditis episodes, n (%) | 41 (30.1) |
| Chest pain | 136 (100.0) |
| Elevated C-reactive protein | 121 (89.0) |
| Fever >39°C | 72 (52.9) |
| Pericardial effusion | 110 (80.9) |
| Pleural effusion | 68 (50.0) |
| Ascites | 11 (8.1) |
| Arthralgia | 41 (30.1) |
| Rash | 15 (11.0) |
| Complications, n (%)§ | 27 (19.9) |
| Cardiac tamponade | 15 (11.0) |
| Myocardial involvement | 1 (0.7) |
| Constriction | 39 (28.7) |
| Corticosteroid dependence | 51 (37.5) |
| Chronic chest pain | 19 (14.0) |

(Continued)
Table 2. (Continued)

| Treatment of presenting episode, n (%) |
|---------------------------------------|
| No treatment or simple analgesia only | 84 (61.8) |
| Colchicine only                       | 26 (19.1) |
| Corticosteroid only                   | 21 (15.4) |
| Colchicine and corticosteroid         | 5 (3.7)   |

IQR indicates interquartile range; and IRP, idiopathic recurrent pericarditis.

* Self-reported ethnicity using questionnaire that included ethnicity categories recommended for use in England and Wales.

† First-degree relative with 1 or more episode(s) of confirmed acute pericarditis.

‡ Specific diagnoses are reported where a diagnosis was observed in 3 or more patients.

§ Myocardial involvement is defined as a raised Troponin I/T, or myocardial inflammation on cardiac magnetic resonance imaging (MRI). Corticosteroid dependence is defined as requiring continuous daily corticosteroids for 6 months or longer. Chronic chest pain is defined as chest pain in the presence of normal investigations (inflammatory markers±ECG and imaging echocardiogram and/or MRI) on 2 or more occasions. Chronic fatigue is defined as patient-reported fatigue between disease flares.

∥ Disease-modifying drugs comprise colchicine, corticosteroid, anakinra, disease-modifying antirheumatic drug, or another biologic drug. Simple analgesia includes nonsteroidal anti-inflammatory drugs.

P=0.028) (Figure 2A, Table S1). Importantly, we identified no association between a history of cardiac tamponade and the development of the common chronic complications of corticosteroid dependence, chronic chest pain or chronic fatigue. Myocardial involvement was also associated with an earlier age of onset (aOR, 0.91 [CI, 0.85–0.97], P=0.0063) (Figure 2B, Table S2). Chronic complications were more common. The most frequent was chronic chest pain, defined as pericarditic chest pain with normal inflammatory markers and without findings consistent with acute pericarditis on examination or investigation on 2 or more occasions, which was reported in 51/136 patients (37.5%).

Corticosteroid dependence, defined as continuous daily corticosteroid use at doses greater than prednisolone 5 mg (or equivalent) for 6 months or longer, was also common, occurring in 39/136 patients (28.7%). A significant minority of corticosteroid-dependent patients developed physical health problems suggestive of corticosteroid toxicity (11/39, 28.2%). Of particular note, 9/39 (23.1%) were diagnosed with osteoporosis or osteopenia, accounting for all cases of these diagnoses in the entire IRP cohort, and 1 patient developed adrenal insufficiency requiring lifelong glucocorticoid replacement. We also observed 1 new diagnosis of hypertension, while 1 patient with pre-existing type 2 diabetes and hypertension required escalation of antihypertensive therapy and the initiation of insulin.

Chronic fatigue, defined as patient-reported fatigue between flares, was reported by 19/136 patients (14.0%). All patients with chronic fatigue also reported chronic chest pain.

Patients with a history of corticosteroid dependence were more likely to report chronic pain (aOR, 2.8 [95% CI, 1.3–6.5], P=0.012) or chronic fatigue (aOR, 4.8 [95% CI, 1.6–14], P=0.0041) than those without (Tables S3 and S4). Those with a history of myocardial involvement were less likely to report chronic pain (aOR, 0.12 [95% CI, 0.0054–0.55], P=0.049) (Table S3). Corticosteroid dependence was also associated with a history of extrapericardial effusion (aOR, 2.6 [95% CI, 1.2–6.3], P=0.023) (Table S5).

Taken together, these clinical data illustrate the frequent problem of corticosteroid dependence among this patient group and suggest that this may be associated with increased risk of chronic symptoms.

Pericarditis in Monogenic SAIDs: Prevalence and Response to Treatment

Pericarditis is often described as a feature of auto-inflammatory diseases, but no previous study has compared its prevalence across the 4 IL-1-mediated monogenic SAIDs. In our cohort of 1910 individuals, we observe pericarditis in each of these conditions, and find that it is most prevalent in MKD (Table 3). At diagnosis, all patients had marked systemic involvement and no patient reported pericardial chest pain as their first symptom. Cardiac tamponade necessitating pericardiocentesis was only observed in one patient with MKD and no cases of pericarditis complicated by myocardial involvement were recorded.

Of the 17 confirmed episodes of pericarditis, 14 (82.4%) occurred before establishment on prophylactic immunomodulatory therapy, 2 while on low-dose colchicine, and 1 while on the anti-IL-1β monoclonal antibody canakinumab. Given the very low incidence of pericarditis in the general population, with population-estimates ranging from 3.3 to 27.7 per 100 000 person-years, our data demonstrate that pericarditis is a definite but uncommon feature of SAID, which typically occurs before initiation of prophylactic immunomodulatory treatment.23,24

Candidate Gene Analysis of MEFV, MVK, NLRP3, and TNFRSF1A in IRP Cases

Having shown that pericarditis is a feature of FMF, MKD, CAPS and TRAPS, we next assessed whether variants in the genes responsible for these conditions are also observed in patients with IRP. MEFV, MVK, NLRP3,
and TNFRSF1A were sequenced in 128 patients with IRP, with a mean coverage of 1484×. More than 99% of bases had been sequenced at a depth sufficient to detect germline mutations (>50×). Moreover, 97% of nucleotides were sequenced at >200× depth, providing sufficient coverage to detect somatic mutations, which is of interest given that somatic mutations are implicated in late-onset autoinflammatory diseases.25,26

We first considered germline mutations that had previously been classified as pathogenic or likely pathogenic by consensus agreement.27 We found no such variants in MVK, NLRP3, or TNFRSF1A. Conversely, 5 patients with IRP (5/128, 3.9%) harbored pathogenic or likely pathogenic variants in the MEFV gene (Table 4). However, all carried a single heterozygous mutation, and therefore did not meet consensus criteria for a
Peet et al. Pericarditis and Autoinflammation

Given that the R121Q (previously known as R92Q) TNFRSF1A variant had previously been reported in patients with IRP of European ancestry, we next investigated whether it was associated with the disease in our cohort.28 This variant is classified as a variant of unknown significance in TRAPS by consensus agreement.27 We found that the allele frequency of R121Q among our 100 patients of non-Finnish European ancestry (5/200, 2.5%) and that described by Cantarini et al (6/262, 2.3%) were not significantly different from that observed among ancestry-matched healthy controls in the gnomAD database (2564/129,036, 2.0%) (P=0.60 and 0.66, respectively).28 This argues against the notion that R121Q has a pathogenic role in IRP.

To determine whether previously unreported variants might be implicated in IRP, we next looked for rare variants predicted to be deleterious by in silico tools. While no such changes were seen in TNFRSF1A, a total of 8 rare deleterious variants were identified in the other 3 genes in 11 individuals (Table 5). Of note, 9 individuals (9/128, 7.0%) carried a rare deleterious variant in the MEFV gene, meaning that 7.8% of patients with IRP (10/128) carried a variant in MEFV that was either known or predicted to be damaging. Of note, all patients with IRP with a candidate MEFV variant had raised inflammatory markers during attacks and none had evidence of myocardial involvement (Table S6).

To further investigate the pathogenic significance of rare deleterious variants in MEFV, we compared their combined frequency in patients with IRP who were of non-Finnish European ancestry (hereafter referred to as European ancestry) to that of all rare deleterious variants in MEFV in ancestry-matched healthy controls in the gnomAD database. In this subgroup of 100 patients, we observe rare variants in MEFV that are predicted to be damaging in patients with IRP more frequently than expected (allele frequency 9/200 versus 2932/12,920, P=0.040) (Table 6). Importantly, the combined frequencies of rare synonymous MEFV variants were comparable in cases and controls, confirming that the 2 groups were appropriately matched (Table S7).

No somatic variants were detected in any of the 4 examined genes.

**DISCUSSION**

IRP is widely regarded as a single system cardiac disease, and current ESC guidelines for the diagnosis of IRP and for recognition of disease recurrence focus solely on pericardial inflammation. However, our findings illustrate that systemic inflammation and localized extrapericardial inflammation, most notably serositis, are common features of the disease, reframing IRP within the spectrum of systemic inflammatory diseases.14 Indeed, we observe an association between the presence of extrapericardial effusion(s) and corticosteroid dependence, suggesting that a more comprehensive approach is indicated when assessing disease activity.

While corticosteroid dependence is known to carry serious risks of complications and impact significantly on patient quality of life, corticosteroids remain the

---

**Table 3. Prevalence of Acute and Recurrent Pericarditis in Monogenic Systemic Autoinflammatory Diseases**

| Disease (causative gene, inheritance) | History of pericarditis |
|--------------------------------------|-------------------------|
|                                      | Acute       | Recurrent |
| Mevalonate kinase deficiency (MKD) (MVK, recessive) | 3.7% (3/82) | 2.4% (2/82) |
| Cryopyrin-associated periodic fever syndrome (CAPS) (NLRP3, dominant) | 1.3% (3/234) | 0.4% (1/234) |
| Familial Mediterranean fever (FMF) (MEFV, recessive) | 0.4% (5/1316) | 0.1% (1/1316) |
| TNF receptor-associated periodic fever syndrome (TRAPS) (TNFRSF1A, dominant) | 0.7% (2/278) | 0.0% (0/278) |

---

**Table 4. Pathogenic or Likely Pathogenic Variants Identified in Idiopathic Recurrent Pericarditis Cases**

| Gene | Variant | HGVS | Consensus classification | Patient ID | Patient ancestry | Ancestry-matched MAF |
|------|---------|------|--------------------------|------------|------------------|---------------------|
| MEFV | c.2080A>G | p.(Met694Val) | Pathogenic | 1 | NFE | 0.0005 |
|      |         |      |                          | 2 | NFE | 0.0005 |
|      | c.2084A>G | p.(Lys695Arg) | Likely pathogenic | 3 | NFE | 0.0068 |
|      |         |      |                          | 4 | NFE | 0.0068 |
|      | c.2177T>C | p.(Val726Ala) | Pathogenic | 5 | Ashkenazi Jewish | 0.0398 |

Variants that have been classified as pathogenic or likely pathogenic by international consensus that were identified on sequencing of 4 candidate genes (MEFV, MKD, NLRP3, TNFRSF1A) in 128 IRP cases.

HGVS indicates Human Genome Variation Society; HGVS, HGVS coding sequence; HGVS, HGVS protein sequence; MAF, minor allele frequency; MEFV, MEFV innate immunity regulator, pyrin; and NFE, non-Finnish European.
second-line treatment recommendation in European guidelines after low-dose colchicine.²¹,²⁹ Notably, the second most common comorbidity among all patients with IRP in this cohort was iatrogenic osteoporosis or osteopenia. Moreover, in our cohort, a history of corticosteroid dependence was associated with chronic chest pain and fatigue. There is a complete lack of data on whether pharmacological treatment of symptoms, in the absence of objective evidence of inflammation, is beneficial, because such cases have been excluded from trials (Table 1). Indeed, the association we observe between corticosteroid dependence and chronic pain may be, in part, driven by the inappropriate treatment of noninflammatory symptoms. This, together with the low early uptake of colchicine in our cohort, with less than half of those presenting with acute pericarditis after publication of the 2015 ESC guidelines receiving colchicine at diagnosis, a finding replicated in a recent US study, further highlight the current barriers to adoption of evidence-based treatment.³ According to the data, a need to understand the mechanisms underlying both the disease and its complications to guide earlier use of targeted interventions, thereby minimizing iatrogenic harm and reducing the risk of chronic sequelae.

In this study we approach this by analyzing 4 candidate genes, in which pathogenic mutations are known to cause IL-1-mediated autoinflammatory disease. In our cohort, a history of corticosteroid dependence was associated with chronic chest pain and fatigue. There is a complete lack of data on whether pharmacological treatment of symptoms, in the absence of objective evidence of inflammation, is beneficial, because such cases have been excluded from trials (Table 1). Indeed, the association we observe between corticosteroid dependence and chronic pain may be, in part, driven by the inappropriate treatment of noninflammatory symptoms. This, together with the low early uptake of colchicine in our cohort, with less than half of those presenting with acute pericarditis after publication of the 2015 ESC guidelines receiving colchicine at diagnosis, a finding replicated in a recent US study, further highlight the current barriers to adoption of evidence-based treatment.³ According to the data, a need to understand the mechanisms underlying both the disease and its complications to guide earlier use of targeted interventions, thereby minimizing iatrogenic harm and reducing the risk of chronic sequelae.

In this study we approach this by analyzing 4 candidate genes, in which pathogenic mutations are known to cause IL-1-mediated autoinflammatory disease. Importantly, we first establish that IRP represents a distinct disease with no patients in our cohort meeting consensus criteria for a genetic diagnosis of FMF, MKD, CAPS, or TRAPS.²⁷ We also did not find any association between 3 of these genes (MVK, NLRP3, and TNFRSF1A) and IRP. This is of particular note in the case of NLRP3 in view of a recent study that showed upregulation of NLRP3 inflammasome activity in the pericardia of patients with recurrent pericarditis complicated by constriction.³⁰ However, our genetic analysis did find that 7.8% of patients with IRP (10/128) harbor variants in MEFV that are either known or predicted to be pathogenic, and we find an association between rare deleterious variants in this gene and IRP, suggesting that the presence of heterozygous variants in MEFV may be associated with an increased risk of the disease. While FMF is generally an autosomal recessive disease, asymptomatic carriers of a single pathogenic MEFV variant have elevated inflammatory markers compared with wild-type controls.³¹ More recent functional work has also demonstrated that neutrophils from asymptomatic MEFV M694V heterozygotes show increased pro-inflammatory activity.³² These findings indicate a gene–dosage effect, whereby gain-of-function mutations in MEFV result in a higher risk of the disease.

### Table 5. Rare Deleterious Variants Identified in Idiopathic Recurrent Pericarditis Cases

| Gene  | Variant Description | HGVSc | HGVSp | In silico predication | Patient ID | Patient ancestry | Ancestry-matched MAF |
|-------|---------------------|-------|-------|----------------------|------------|------------------|----------------------|
| MEFV  | c.267T>A p.(Leu9Gln) | …     | Damage| 6                    | NFE        | Novel            | 7.74 x 10⁻⁵          |
|       | c.124C>T p.(Arg42Trp)| …     | Damage| 7                    | NFE        | 1.78 x 10⁻⁵      |                      |
|       | c.1337A>C p.(Glu446Ala)| …     | Damage| 8                    | NFE        | 7.74 x 10⁻⁵      |                      |
|       | c.1759+1G>A          | …     | Damage| 10                   | NFE        | Novel            | 7.74 x 10⁻⁵          |
|       | c.2080A>G p.(Met694Val)| …     | Damage| 1                    | NFE        | 0.0005           |                      |
|       | c.2084A>G p.(Lys695Arg)| …     | Damage| 3                    | NFE        | 0.0068           |                      |
| MVK   | c.677+7delT          | …     | Damage| 11                   | NFE        | Novel            | 7.74 x 10⁻⁵          |
| NLRP3 | c.2711C>T p.(Ser908Leu)| …     | Damage| 12                   | NFE        | 1.78 x 10⁻⁵      |                      |

Rare deleterious variants (ancestry matched minor allele frequency <1% that are predicted in silico to be damaging [scaled CADD score >10]) identified on sequencing of 4 candidate genes (MEFV, MVK, NLRP3, TNFRSF1A) in 128 IRP cases.

HGVS indicates Human Genome Variation Society; HGVSc, HGVS coding sequence; HGVSp, HGVS protein sequence; MAF, minor allele frequency; MEFV, MEFV innate immunity regulator, pyrin; NFE, non-Finnish European; MVK, mevalonate kinase; and NLRP3, NLR family pyrin domain containing 3.

### Table 6. Burden Association Test of Rare Deleterious Variants in MEFV in Individuals of European Descent With IRP

| Gene | Combined frequency of rare deleterious variants | P value |
|------|-------------------------------------------------|---------|
| MEFV | 9/200 (4.5%)                                    | 0.040*  |

Combined allele frequency of rare deleterious variants (number of variants divided by the total number of alleles) among the 100 NFE IRP cases and the 64,600 ancestry-matched controls taken from the gnomAD database; comparison in made using a 1-sided Fisher test. *P<0.05.

gnomAD indicates genome aggregation database; IRP, idiopathic recurrent pericarditis; MEFV, MEFV innate immunity regulator, pyrin; and NFE, non-Finnish European.
in increased innate immune activity. Accordingly, our findings suggest that the presence of a single MEFV mutation may predispose carriers to the development of recurrent pericarditis.

While these monogenic SAIDs are often said to manifest with pericarditis, the prevalence of pericarditis has only previously been investigated in FMF. In our cohort, we observe pericarditis in all 4 diseases examined. We also demonstrate that pericarditis typically occurs before establishment on prophylactic therapy targeting the IL-1 axis. Complete disease control using these agents is now widely achieved in these conditions, and this may both result in an underestimate of the natural incidence of pericarditis in SAIDs in our study while also providing a paradigm for how the treatment of IRP might be approached.

The concept of treat-to-target is widely used in rheumatology and in the management of SAIDs, with the aim of obtaining optimal disease responses with minimal treatment-associated morbidity. The approach involves the identification of a set target at a defined treatment interval, with a stepwise plan for escalation should the treatment target not be reached. This has clear advantages in standardizing treatment while also facilitating shared decision making with patients. Importantly, this strategy has been shown to improve remission rates in randomized controlled trials and is the recommended treatment approach in the 4 monogenic SAIDs included in this study. For example, in FMF, consensus guidance recommends gradual escalation of colchicine dose, routinely up to 3 mg/d in adults, guided by treatment response, and, in patients truly refractory to higher doses of colchicine, anti-IL-1 agents are then added to treatment. Recognition of IRP as falling within the spectrum of SAID should facilitate a culture change away from overreliance on corticosteroids, and their associated harms, to a more consistent, targeted approach.

Importantly though, the treat-to-target strategy relies on validated measures of disease activity, an area that has been neglected in research into IRP. Indeed, the difficulty of distinguishing disease activity from disease damage in chronic diseases, and specifically in autoinflammatory diseases, is well recognized. In previous studies of IRP, the number or timing of recurrences has been widely used. However, in IRP there is significant heterogeneity in the presentation of disease recurrence, both between and within patients, and in the definitions used by studies, which limits the generalizability and reproducibility of such research. This is particularly pertinent given that more than one third of our patients report chest pain without evidence of acute pericardial inflammation on investigation. Consensus guidance on the management of SAID advocates the parallel use of disease activity and disease damage scores, to facilitate titration of pharmacological interventions against disease activity, while also monitoring for complications that may necessitate alternative treatment approaches and for which the benefit of immunomodulatory drugs may not have been proven. Given the adverse outcomes associated with prolonged corticosteroid use and both the potential side effects and cost of newer biologic agents, distinguishing between active inflammatory disease amenable to immunomodulation and established noninflammatory complications is crucial to minimize treatment-associated harms. The development and validation of disease activity and damage scores are therefore urgently needed to both improve patient care through unbiased disease monitoring and to facilitate robust, reproducible research into this condition.

Our study carries a number of limitations. First, the retrospective design means our analysis will not capture features that were not documented, reported, or investigated contemporaneously. As such there is a risk of information bias, and, accordingly, prospective studies of pericarditis are much needed. Additionally, our IRP cohort was recruited through a national referral center, which has likely resulted in an enrichment of more severe phenotypes in our cohort, and there is an outstanding need for collection of data in large, unselected cohorts and, importantly, in patients of diverse ethnicities. Finally, given the observational design of the study, we are not able to identify causal relationships.

For our genetic analysis, we utilize publicly available controls, listed in the gnomAD database, meaning that sequencing was performed on different platforms and that detailed information about control phenotypes was not available. To assess the possibility of mismatching between cases and controls, we conducted a parallel analysis of rare synonymous variants, which found no significant differences between the 2 groups, suggesting they are well matched (Table S4). Nonetheless, our findings will need to be validated in a second cohort, and, importantly, in patients of non-European ancestry, which our study was underpowered to consider. Finally, the assessment of novel or uncategorized variants based on in silico pathogenicity prediction must be interpreted with caution, and functional testing of novel candidate variants is needed to establish their potential contribution to IRP.

CONCLUSIONS

An increasing body of evidence, including our finding that damaging variants in MEFV may confer an increased risk of IRP, implicates autoinflammation and the IL-1 pathway in the pathogenesis of this disease. Despite this, corticosteroid use remains widespread and dependence is associated with poor outcomes. Taken together, these data support reduced reliance
on corticosteroids in IRP management and wider uptake of innate immune modulators targeted to inflammatory activity, while ongoing work continues to investigate the exact mechanisms by which autoinflammatory pathways drive this debilitating disease.

ARTICLE INFORMATION
Received December 10, 2021; accepted March 17, 2022.

Affiliations
National Amyloidosis Centre, Royal Free London NHS Foundation Trust & Division of Medicine University, College London, London, United Kingdom (C.J.P., D.R., E.O., C.P., B.R.M., M.W.R., H.J.L.); and Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom (C.J.P., F.D.).

Sources of Funding
This work is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/19/67/34997).

Disclosures
CP reports receiving speaker fees from Sobi. FC reports receiving funding and consultancy fees from Boehringer Ingelheim. HJL reports receiving consultant fees from Novartis and Sobi. The remaining authors have no disclosures to report.

Supplemental Material
Data S1
Table S1–S7
Figure S1

REFERENCES
1. Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, Klein AL. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68:2311–2328. doi: 10.1016/j.jacc.2016.07.785
2. Klein A, Cremer P, Kontzias A, Furqan M, Forsythe A, Crotty C, Lim-ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–2237. doi: 10.1016/S0140-6736(13)62709-9
3. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–414. doi: 10.7326/0003-4819-155-7-201110040-00339
4. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Bepariq F, Demarie D, Ferro S, Forno D, Maestroni S, et al. Colchicine for recurrent pericarditis. JAMA. 2016;316:1906–1912. doi: 10.1001/jama.2016.15926
5. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, et al. Phase 3 trial of interleukin-1 trap ribonacopt in recurrent pericarditis. NEJM. 2020;383:41–48. doi: 10.1056/NEJMoa2027892
6. Adler Y, Charron P, Imazio M, Madano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Kingley K, Lions C, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36:2921–2964. doi: 10.1093/eurheartj/ehv318
7. Talmud P, Tybjærg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P, Humphries S. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis. 1991;99:137–141. doi: 10.1016/0021-9150(91)90053-6
8. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:1062–1067. doi: 10.1093/nar/gkx1153
9. Sarraste de Mentherec C, Terrière S, Pugrière D, Ruiz M, Demaille J, Toutou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 2003;31:282–286. doi: 10.1093/nar/gkg031
10. Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksevitjch I, Lesage S, Waterham H, Wise C, Sarraste de Mentherec C, et al. The interferon-alpha autoinflammation mutational registry: update with new genes and functions. Human Mutat. 2008;29:803–808. doi: 10.1002/humu.20720
11. Van Gijn ME, Cecherini I, Shinar Y, Carbo EC, Sifistra M, Arostegui JR, Sarrabay G, Rowczenio D, Omoyiım E, Atlööj M, et al. New workflow for classification of genetic variants’ pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Gen. 2018;55:530–537. doi: 10.1038/jmedgenet.2017.10921
12. Toutou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode G, Shoham N, Aganna E, Hung J-P, Wise C, et al. INFEVERS: an evolving mutation database for autoinflammatory syndromes. Human Mutat. 2004;24:194–198. doi: 10.1002/humu.20080
13. Karczewski KJ, Francioli LC, Tao G, Cummings BB, Afzööji D, Wang Q, Collins RL, Larichia KM, Ganna A, Birnbaum DP, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–443. doi: 10.1038/s41586-020-2306-7
14. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:886–894. doi: 10.1093/nar/gky1016
15. Kyöö V, Sillial J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130:1601–1606. doi: 10.1161/CIRCULATIONAHA.114.010576
16. Imazio M, Cecchi E, Demichelis B, Chinghialo A, Lema S, Demarie D, Ghiso A, Pomari F, Belli R, Trinchero R. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987–1991. doi: 10.1001/archinte.165.17.1987
17. Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksevitjch I, Lesage S, Waterham H, Wise C, Sarraste de Mentherec C, et al. The interferon-alpha autoinflammation mutational registry: update with new genes and functions. Human Mutat. 2008;29:803–808. doi: 10.1002/humu.20720
18. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:886–894. doi: 10.1093/nar/gky1016
19. Kyöö V, Sillial J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130:1601–1606. doi: 10.1161/CIRCULATIONAHA.114.010576
20. Imazio M, Cecchi E, Demichelis B, Chinghialo A, Lema S, Demarie D, Ghiso A, Pomari F, Belli R, Trinchero R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94:498–510. doi: 10.1136/hrt.2006.104607
21. Rowczewski DM, Gomes SM, Aróstegui JI, Mensa-Villaro A, Omoymrni E, Troher J, Baginska A, Bario-Mazo A, Pelegrin P, Savic S, et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mutations—UK single center experience. Front Immunol. 2017;8:1410. doi: 10.3389/fimmu.2017.01410
22. Cecherini I, Rusmini M, Arostegui JI. Genetic aspects of investigating and understanding autoinflammation. In: Hashkes PJ, Laxer RM, Simon A, eds. Textbook of Autoinflammation. 1st ed. Springer; 2019:19–48.
27. Shinar Y, Ceccherini I, Rowczenio D, Aksentijevich I, Arostegui J, Ben-Chétrit E, Boursier G, Gattorno M, Hayrapetyan H, Ida H, et al. ISSAID/EMQN best practice guidelines for the genetic diagnosis of monogenic autoinflammatory diseases in the next-generation sequencing era. Clin Chem. 2020;66:525–536. doi: 10.1093/clinchem/hvaa024

28. Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacononi F, Rigante D, Brambilla G, Penco S, Briz MG, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol. 2012;101:525–531. doi: 10.1007/s00392-012-0422-8

29. Miloslavsky EM, Naden RP, Bijlsma JWJ, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire J-F, Buttgereit F, Gelfand JM, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76:543–548. doi: 10.1136/annrhumdis-2016-210002

30. Mauro AG, Bonaventura A, Vecchié A, Mezzaroma E, Carbone S, Narayan P, Potere N, Cannata A, Paolini JF, Bussani R, et al. The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches. JACC: Basic Transl Sci. 2021;6:137–150. doi: 10.1016/j.jacbts.2020.11.016

31. Lachmann HJ, Şengül B, Yavuzer TJ, Booth DP, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatol. 2006;45:746–750. doi: 10.1093/rheumatology/ke279

32. Stoler I, Freytag J, Orak B, Unterwärther N, Henning S, Heim K, von Bernuth H, Krüger R, Winkel S, Eschenhagen P, et al. Gene-dose effect of MEFV gain-of-function mutations determines ex vivo neutrophil activation in familial mediterranean fever. Front Immunol. 2020;11:716. doi: 10.3389/fimmu.2020.00716

33. Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Linveh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997;90:643–647. doi: 10.1093/qjmed/90.10.643

34. van Vollenhoven R. Treat-to-target in rheumatoid arthritis — are we there yet? Nat Rev Rheumatol. 2019;15:180–186. doi: 10.1038/s41584-019-0170-5

35. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–269. doi: 10.1016/S0140-6736(04)16678-2

36. Lachmann HJ, Brogan PA. Autoinflammation: when is familial Mediterranean fever “severe”? Nat Rev Rheumatol. 2016;12:256–268. doi: 10.1038/nrrheum.2016.55
Supplemental Material
Data S1.

Supplemental Methods

Details of the custom next generation sequencing panels used

NGS was performed using a custom TruSeq panel (Illumina) (n=44) or custom AmpliSeq panel (Illumina) (n=84). The TruSeq panel consists of 377 amplicons covering a total of 49.275 kB. These comprise the coding regions and flanking intron sequences of 20 genes: ADA2, CARD14, IL1RN, IL36RN, LPIN2, MEFV, MVK, NLRC4, NLRP12, NLRP3, NOD2, PLCG2, PSMB4, PSMB8, PSMB9, PSTPIP1, SH3BP2, TNFRSF1A, TMEM173 (STING), TNFAIP3. For this panel, NGS libraries were prepared using the TruSeq Custom Amplicon method (Illumina). The AmpliSeq panel consists of 393 amplicons covering a total of 65.807 kB. These comprise the targets of the TruSeq panel and an additional four genes: OTULIN, RBCK1, SLC29A3, UBA1. For the AmpliSeq panel, NGS libraries were prepared using the AmpliSeq Custom Amplicon Method (Illumina). For both panels, sequencing was performed on the Illumina MiSeq platform.
Table S1. Multiple logistic regression model of cardiac tamponade.

|                    | Reference level | Adjusted OR (95% CI) | p value |
|--------------------|-----------------|----------------------|---------|
| (Intercept)        | -               | 1.44 (n/a)           | n/a     |
| Sex                | Female          | 0.445 (0.177 – 1.07) | 0.0752  |
| Age of onset       | -               | 0.956 (0.915 – 0.993) | 0.0275* |

CI: confidence interval; OR: odds ratio. *p<0.05;**p<0.01;***p<0.001.
Table S2. Multiple logistic regression model of myocardial involvement.

|                  | Reference level | Adjusted OR (95% CI)       | p value  |
|------------------|-----------------|----------------------------|----------|
| (Intercept)      | -               | 2.92 (n/a)                 | n/a      |
| Sex              | Female          | 0.846 (0.260 – 2.78)       | 0.779    |
| Age of onset     | -               | 0.911 (0.846 – 0.969)      | 0.00632**|
| Chronic pain     | Absent          | 0.101 (0.00538 – 0.549)    | 0.0315*  |

CI: confidence interval; OR: odds ratio. *p<0.05; **p<0.01; ***p<0.001.
Table S3. Multiple logistic regression model of chronic chest pain.

|                                | Reference level | Adjusted OR (95% CI) | p value |
|--------------------------------|-----------------|----------------------|---------|
| (Intercept)                    | -               | 0.752 (n/a)          | n/a     |
| Sex                            | Female          | 0.575 (0.267 – 1.23) | 0.153   |
| Age of onset                   | -               | 0.996 (0.965 – 1.03) | 0.794   |
| History of corticosteroid dependence | Absent        | 2.82 (1.26 – 6.45)  | 0.0121* |
| History of myocardial involvement | Absent        | 0.120 (0.00639 – 0.672) | 0.0489* |

CI: confidence interval; OR: odds ratio. *p<0.05; **p<0.01; ***p<0.001.
Table S4. Multiple logistic regression model of chronic fatigue.

| Reference level                        | Adjusted OR (95% CI)              | p value |
|----------------------------------------|-----------------------------------|---------|
| (Intercept)                            | 0.101 (n/a)                       | n/a     |
| Sex                                    | Female                            | 0.413 (0.121 – 1.24) | 0.129 |
| Age of onset                           | -                                 | 1.01 (0.965 – 1.05)  | 0.802 |
| History of corticosteroid dependence   | Absent                            | 4.75 (1.66 – 14.4)   | 0.00414** |

CI: confidence interval; OR: odds ratio. *p<0.05;**p<0.01;***p<0.001.
Table S5. Multiple logistic regression model of corticosteroid dependence.

|                          | Reference level | Adjusted OR (95% CI) | p value |
|--------------------------|-----------------|----------------------|---------|
| (Intercept)              | -               | 0.0746 (n/a)         | n/a     |
| Sex                      | Female          | 0.530 (0.225 – 1.22) | 0.139   |
| Age of onset             | -               | 1.03 (0.995 – 1.06)  | 0.104   |
| Chronic chest pain       | Absent          | 3.36 (1.49 – 7.80)   | 0.00402** |
| History of extra-pericardial effusion | Absent          | 2.64 (1.16-6.28)    | 0.0231*   |

CI: confidence interval; OR: odds ratio. *p<0.05;**p<0.01;***p<0.001.
Table S6. Demographics and clinical features of patients with idiopathic recurrent pericarditis, stratified by MEFV genotype.

| Demographics | Individuals with no variant in MEFV (n=118) | Individuals with a variant in MEFV (n=10) |
|--------------|-------------------------------------------|-------------------------------------------|
| Sex [female], n (%) | 56 (47.5) | 7 (70.0) |
| Onset, median [IQR] | 31.00 [23.0 – 39.0] | 35.50 [26.0 – 40.5] |
| Ancestry, n (%)* | | |
| African ancestry | 10 (8.5) | 0 (0.0) |
| Ashkenazi Jewish ancestry | 4 (3.4) | 1 (10.0) |
| Mixed ancestry | 3 (2.5) | 0 (0.0) |
| Non-Finnish European ancestry | 91 (77.1) | 9 (90.0) |
| Other ancestry | 6 (5.1) | 0 (0.0) |
| South Asian ancestry | 3 (2.5) | 0 (0.0) |
| Unknown or not disclosed | 1 (0.8) | 0 (0.0) |
| Family history, n (%)# | 5 (4.2) | 1 (10.0) |
| Year of first acute pericarditis diagnosis, n (%) | | |
| 1991 – 2015 | 76 (64.4) | 8 (80.0) |
| 2016 - 2020 | 42 (35.6) | 2 (20.0) |
| Clinical features of acute pericarditis episodes, n (%) | | |
| Chest pain | 118 (100.0) | 10 (100.0) |
| Elevated C-reactive protein | 106 (89.8) | 10 (100.0) |
| Fever over 39°C | 63 (53.4) | 4 (40.0) |
| Pericardial effusion | 97 (82.2) | 6 (60.0) |
| Pleural effusion | 59 (50.0) | 4 (40.0) |
| Ascites | 11 (9.3) | 0 (0.0) |
| Arthralgia | 36 (30.5) | 3 (30.0) |
| Rash | 14 (11.9) | 0 (0.0) |
| Complications, n (%)‡ | | |
| Cardiac tamponade | 23 (19.5) | 4 (40.0) |
| Myocardial involvement | 14 (11.9) | 0 (0.0) |
| Constriction | 1 (0.8) | 0 (0.0) |
| Corticosteroid dependence | 35 (30.0) | 2 (20.0) |
| Chronic chest pain | 43 (36.4) | 4 (40.0) |
| Chronic fatigue | 18 (15.3) | 1 (10.0) |
| Management‡ | | |
| Number of drugs tried, median [IQR, range] | 2 [1 – 3, 0 – 7] | 1 [1 – 3, 0 – 5] |
| No treatment or simple analgesia only, n (%) | 7 (5.9) | 1 (10.0) |
| Colchicine, n (%) | 110 (93.2) | 9 (90.0) |
| Corticosteroid, n (%) | 68 (57.6) | 4 (40.0) |
| Anakinra, n (%) | 16 (13.6) | 2 (20.0) |
| Disease modifying anti-rheumatic drug(s), n (%) | 23 (19.5) | 2 (20.0) |
| Other biologic drug, n (%) | 3 (2.5) | 0 (0.0) |
| Pericardiectomy | 1 (0.7) | 0 (0.0) |
| Treatment of presenting episode, n (%)§ | | |
| No treatment or simple analgesia only | 71 (60.2) | 7 (70.0) |
| Colchicine only | 23 (19.5) | 1 (10.0) |
| Corticosteroid only | 20 (17.0) | 1 (10.0) |
| Colchicine and corticosteroid | 4 (3.4) | 1 (10.0) |

*Variants classified as pathogenic/likely pathogenic or predicted to be pathogenic in silico (minor allele frequency <0.01, CADD >10).

*Ancestry categorisation was performed to align with the groups defined on the Genome Aggregation Database (gnomAD).

#First degree relative with one or more episode(s) of confirmed acute pericarditis.
Myocardial involvement is defined as a raised Troponin I/T, or myocardial inflammation on cardiac MRI. Corticosteroid dependence is defined as requiring continuous daily corticosteroids for six months or longer. Chronic chest pain is defined as chest pain in the presence of normal investigations (inflammatory markers +/- ECG and imaging) on 2 or more occasions.

Disease modifying drugs comprise colchicine, corticosteroid, anakinra, disease modifying anti-rheumatic drug or other biologic drug. Simple analgesia includes non-steroidal anti-inflammatory drugs.
### Table S7. Burden association test of rare synonymous variants in individuals of European (NFE) descent.

| Gene | Combined frequency of rare synonymous variants | | p value |
|------|-----------------------------------------------|---|---------|
|      | Allele frequency in cases | Allele frequency in controls* |                           |
| MEFV | 2.0% (4/200) | 1.6% (2031/129198) | 0.386               |

This table shows the combined allele frequency of rare synonymous variants (number of variants divided by the total number of alleles) among the 100 NFE IRP cases and the 64,600 ancestry matched controls taken from the gnomAD database; comparison is made using a one-sided Fisher’s test and values <0.05 are considered statistically significant.

*Unselected controls comprise exomes/genomes of NFE individuals listed on the genome aggregation database (gnomAD v2.1.1). MAF: minor allele frequency; NFE: non-Finnish European.
Figure S1. Recruitment and follow up of individuals with IRP by year.

Recruitment and follow up of individuals with IRP by year. Line graph showing the number of cases (A) where follow up data was available in each year (B) that had their first visit in each year and (C) that had their most recent (last) study visit in each year.